Sensitivity of a novel model of mammary cancer stem cell-like cells to TNF-related death pathways
Tóm tắt
Cancer stem cells (CSC) are resistant to radiation and chemotherapy and play a significant role in cancer recurrence and metastatic disease. It is therefore important to identify alternative strategies, such as immunotherapies that can be used to control this refractory population. A CD44+CD24−/low subpopulation of cells within the B6 PyMT-MMTV transgenic mouse-derived AT-3 mammary carcinoma cell line was identified, which had CSC-like characteristics, including pluripotency and a resistance to chemo- and radiotherapy. Therefore, unlike xenograph models that require immunocompromised settings, this novel system may provide a means to study immune-mediated responses against CSC-like cells. The immunobiology of the AT-3 CSC-like cell population was studied by their surface molecule expression profile and their sensitivity to specified cell death pathways. Comparable levels of Rae-1, CD155, CD54 and higher levels of Fas and DR5 were expressed on the AT-3 CSC-like cells compared to non-CSC-like tumor cells. Expression correlated with an in vitro sensitivity to cell death by NK cells or through the ligation of the death receptors (Fas or DR5), by their ligands or anti-Fas and anti-DR5 mAbs. Indeed, compared to the rest of the AT-3 tumor cells, the CD44+CD24−/low subpopulation of cells were more sensitive to both Fas- and TRAIL-mediated cell death pathways. Therefore, despite the refractory nature of CSC to other conventional therapies, these CSC-like cells were not inherently resistant to specified forms of immune-mediated cell death. These results encourage the continued investigation into immunotherapeutic strategies as a means of controlling breast CSC, particularly through their cell death pathways.
Tài liệu tham khảo
Cobaleda C, Cruz JJ, Gonzalez-Sarmiento R, Sanchez-Garcia I, Perez-Losada J (2008) The emerging picture of human breast cancer as a stem cell-based disease. Stem Cell Rev 4:67–79. doi:10.1007/s12015-008-9012-6
Dontu G, Liu S, Wicha MS (2005) Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev 1:207–213. doi:10.1385/SCR:1:3:207
Baumann M, Krause M, Hill R (2008) Exploring the role of cancer stem cells in radioresistance. Nature Rev Cancer 8:545–554. doi:10.1038/nrc2419
Eyler CE, Rich JN (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol Off J Am Soc Clin Oncol 26:2839–2845. doi:10.1200/JCO.2007.15.1829
Li X, Lewis MT, Huang J et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679. doi:10.1093/jnci/djn123
Woodward WA, Bristow RG (2009) Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semin Radiat Oncol 19:87–95. doi:10.1016/j.semradonc.2008.11.003
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988. doi:10.1073/pnas.0530291100
Oliveira LR, Jeffrey SS, Ribeiro-Silva A (2010) Stem cells in human breast cancer. Histol Histopathol 25:371–385
Schmidt C (2008) Lapatinib study supports cancer stem cell hypothesis, encourages industry research. J Natl Cancer Inst 100:694–695. doi:10.1093/jnci/djn168
Shipitsin M, Polyak K (2008) The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 88:459–463. doi:10.1038/labinvest.2008.14
Ginestier C, Hur MH, Charafe-Jauffret E et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567. doi:10.1016/j.stem.2007.08.014
Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151–160. doi:10.1038/nrclinonc.2010.223
Locher C, Conforti R, Aymeric L et al (2010) Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci 1209:99–108. doi:10.1111/j.1749-6632.2010.05763.x
Stewart TJ, Greeneltch KM, Reid JE, Liewehr DJ, Steinberg SM, Liu K, Abrams SI (2009) Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells. J Cell Mol Med 13:3939–3950. doi:10.1111/j.1582-4934.2009.00685.x
Stewart TJ, Abrams SI (2007) Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol 179:2851–2859
Nakayama M, Harada N, Okumura K, Yagita H (2003) Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun 306:819–825
Latour S, Fridman WH, Daeron M (1996) Identification, molecular cloning, biologic properties, and tissue distribution of a novel isoform of murine low-affinity IgG receptor homologous to human Fc gamma RIIB1. J Immunol 157:189–197
Stewart TJ, Drane D, Malliaros J, Elmer H, Malcolm KM, Cox JC, Edwards SJ, Frazer IH, Fernando GJ (2004) ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine 22:3738–3743. doi:10.1016/j.vaccine.2004.03.026
Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, Smyth MJ (2010) DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 184:902–911. doi:10.4049/jimmunol.0903225
Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17:1253–1270. doi:10.1101/gad.1061803
Takeda K, Yamaguchi N, Akiba H et al (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199:437–448. doi:10.1084/jem.20031457
Keysar SB, Jimeno A (2010) More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther 9:2450–2457. doi:10.1158/1535-7163.MCT-10-0530
Sneddon JB, Werb Z (2007) Location, location, location: the cancer stem cell niche. Cell Stem Cell 1:607–611. doi:10.1016/j.stem.2007.11.009
Borovski T, De Sousa EMF, Vermeulen L, Medema JP (2011) Cancer stem cell niche: the place to be. Cancer Res 71:634–639. doi:10.1158/0008-5472.CAN-10-3220
Hurt EM, Farrar WL (2010) Purification and characterization of cancer stem cells. In: Farrar WL (ed) Cancer stem cells, 1st edn. Cambridge University Press, New York, NY, pp 1–14
Nakshatri H, Srour EF, Badve S (2009) Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther 4:50–60
Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A (2009) TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 35:280–288. doi:10.1016/j.ctrv.2008.11.006
Ginestier C, Liu S, Diebel ME et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Investig 120:485–497. doi:10.1172/JCI39397
Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364:806–809. doi:10.1038/364806a0
Cretney E, Takeda K, Smyth MJ (2007) Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 39:280–286. doi:10.1016/j.biocel.2006.10.005
Wu GS (2009) TRAIL as a target in anti-cancer therapy. Cancer Lett 285:1–5. doi:10.1016/j.canlet.2009.02.029
Abdulghani J, El-Deiry WS (2010) TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 14:1091–1108. doi:10.1517/14728222.2010.519701
Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E, Lopez-Rios F, Fujiwara K, Matsui WH, Hidalgo M (2010) A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 9:2582–2592. doi:10.1158/1535-7163.MCT-10-0370
Deonarain MP, Kousparou CA, Epenetos AA (2009) Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs 1:12–25